Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 12;87(6):3988-3993.
doi: 10.1097/MS9.0000000000003350. eCollection 2025 Jun.

Severe hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in a patient with HIV/AIDS: a case report

Affiliations
Case Reports

Severe hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in a patient with HIV/AIDS: a case report

Dipesh Kumar Rohita et al. Ann Med Surg (Lond). .

Abstract

Introduction and importance: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder marked by immune system dysregulation, leading to a severe inflammatory response that can affect multiple organs. It can be triggered by infections, and HLH secondary to disseminated histoplasmosis remains poorly understood, with uncertain guidelines on immunosuppressive therapy. Early diagnosis and prompt treatment are critical in preventing fatal outcomes, but challenges in diagnosis complicate this process, particularly in immunocompromised patients.

Case presentation: A 51-year-old immunocompromised woman with asthma, gastritis, and anemia presented with fever, malaise, weight loss, and respiratory symptoms. Initial workup revealed pancytopenia, elevated ferritin levels, and an HIV diagnosis with a low CD4 count. Suspecting HLH, she was treated with antiretrovirals, antifungals, and steroids. Her condition worsened, and she developed MRSA sepsis, metabolic acidosis, and multiorgan failure. Histoplasmosis was confirmed, and treatment with liposomal amphotericin B was initiated. Unfortunately, she suffered a cardiac arrest and died on day 11. Postmortem findings confirmed disseminated histoplasmosis-induced HLH.

Clinical discussion: HLH is a rare but severe immune activation disorder causing systemic inflammation, multi-organ failure, and high mortality. It can be primary (genetic) or secondary. Diagnosis follows HLH-2004 criteria, and treatment includes immunosuppressive therapy and hematopoietic cell transplantation.

Conclusion: This case illustrates the complexities of diagnosing HLH in immunocompromised patients. Delays in obtaining critical lab results and initiating treatment contributed to the patient's rapid deterioration. Early intervention and careful monitoring are crucial in managing such complex cases, where timely diagnosis can significantly impact patient outcomes.

Keywords: case report; cytokine storm; disseminated histoplasmosis; fever of unknown origin; hemophagocytic lymphohistiocytosis.

PubMed Disclaimer

Conflict of interest statement

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. None.

Figures

Figure 1.
Figure 1.
Chest x-ray and CT chest showing multiple bilateral pulmonary nodules.
Figure 2.
Figure 2.
CT scan of the abdomen and pelvis with contrast.

Similar articles

References

    1. Henter J-I. Hemophagocytic lymphohistiocytosis. N Engl J Med 2025;392:584–98. - PubMed
    1. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol 2013;161:609–22. - PubMed
    1. Bichon A, Bourenne J, Allardet-Servent J, et al. . High mortality of HLH in ICU regardless etiology or treatment. Front Med (Lausanne) 2021;8:735796. - PMC - PubMed
    1. Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Practice & Research Clinical Rheumatology 2020;34:101515. - PubMed
    1. Wu Y, Sun X, Kang K, et al. . Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms. J Hematol Oncol 2024;17:106. - PMC - PubMed

Publication types

LinkOut - more resources